title: Moderate to severe acne in adolescents with skin of color: benefits of a fixed combination clindamycin phosphate 1.2% and benzoyl peroxide 2.5% aqueous gel.
abstract: OBJECTIVE
  Acne is common in adolescents and especially difficult to manage in people with color. A fixed combination of clindamycin phosphate and benzoyl peroxide (BPO) (clindamycin phosphate 1.2%/BPO 2.5% gel) was evaluated to determine its utility in treating moderate to severe acne in adolescents with skin of color.
  
  
  METHODS
  Three hundred thirty-seven adolescent acne subjects (aged 12 to <18 years) with skin of color were evaluated from 2 multicenter, double-blind studies. Subjects were randomized to receive clindamycin phosphate 1.2%/BPO 2.5% gel or vehicle, once daily for 12 weeks. Efficacy and tolerability were evaluated. Data were compared with an adolescent (A) and skin of color (B) cohort from the same pivotal study enrolling 2,813 subjects.
  
  
  RESULTS
  Superior mean percent reductions in inflammatory, noninflammatory, and total lesion counts were observed in subjects receiving clindamycin phosphate 1.2%/BPO 2.5% gel compared to vehicle. At week 12, clindamycin phosphate 1.2%/BPO 2.5% gel showed similar lesion reduction compared to groups A and B (P<0.001). Treatment success with clindamycin phosphate 1.2%/BPO 2.5% gel, assessed by investigator and subject, was superior to vehicle and comparable to that seen in groups A and B (P<0.001). Clindamycin phosphate 1.2%/ BPO 2.5% gel was associated with a low incidence of treatment-related AEs and a favorable cutaneous tolerability profile.
  
  
  CONCLUSIONS
  Clindamycin phosphate 1.2%/BPO 2.5% gel has been shown to be effective, safe, and well tolerated in moderate to severe acne in adolescents with skin of color.
authors: Rady Children's Hospital, San Diego, CA, USA. leichenfield@rchsd.org
authors: Lawrence F
authors: LF
authors: Eichenfield
authors: Andrew C
authors: AC
authors: Krakowski
mesh_terms: D000293:Adolescent; D002648:Child; D005260:Female; D006801:Humans; D008297:Male; D000152:Acne Vulgaris / Q000188:drug therapy / Q000473:pathology; D000900:Anti-Bacterial Agents / Q000009:adverse effects / Q000627:therapeutic use; D001585:Benzoyl Peroxide / Q000009:adverse effects / Q000627:therapeutic use; D002981:Clindamycin / Q000009:adverse effects / Q000627:therapeutic use; D003879:Dermatologic Agents / Q000009:adverse effects / Q000627:therapeutic use; D004311:Double-Blind Method; D004338:Drug Combinations; D000091762:Ethnic and Racial Minorities; D005782:Gels; D012720:Severity of Illness Index; D016896:Treatment Outcome
chemical_list: D000900:Anti-Bacterial Agents; D001585:Benzoyl Peroxide; D002981:Clindamycin; C466951:clindamycin phosphate benzoyl peroxide combination; D003879:Dermatologic Agents; D004338:Drug Combinations; D005782:Gels